STOCK TITAN

Oramed grants CEO Nadav Kidron 629K conditional shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Oramed Pharmaceuticals granted President and CEO Nadav Kidron two direct restricted stock awards on November 12, 2026. One covers 629,000 shares and vests only if the company’s return on equity for fiscal 2026 exceeds 18%. If that condition is met, half vests when the audited fiscal 2026 financial statements are published and half six months later, subject to continued service; otherwise, all shares are forfeited.

The second award covers 688,000 shares for annual awards for fiscal years 2027 and 2028. It vests in two groups of 344,000 shares, each in 12 substantially equal quarterly installments beginning January 1, 2027, and January 1, 2028, respectively, subject to continued service. No annual award will be granted to Kidron for fiscal 2028.

Insider KIDRON NADAV
Role President and CEO
Type Security Shares Price Value
Grant/Award Common Stock F1 629,000 -- --
Grant/Award Common Stock F2 688,000 -- --
Holdings After Transaction: Common Stock — 5,457,505 shares (Direct)
Holdings Before and After: Common Stock, 4,140,505 to 5,457,505 shares (Direct)
Footnotes (2)
  1. F1. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 629,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan. The shares vest only if the issuer's return on equity for fiscal year 2026 exceeds 18%, in which case 50% vest on the date the issuer's audited fiscal year 2026 financial statements are published and 50% vest six months thereafter, subject to the reporting person's continued service. If the condition is not met, all of the shares will be forfeited.
  2. F2. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 688,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual awards for fiscal years 2027 and 2028. Of these shares, 344,000 vest in twelve substantially equal quarterly installments beginning January 1, 2027, and 344,000 vest in twelve substantially equal quarterly installments beginning January 1, 2028, in each case subject to the reporting person's continued service. No annual award will be granted to the reporting person for fiscal year 2028.
Conditional restricted stock award 629,000 shares Granted November 12, 2026; vests only if fiscal 2026 return on equity exceeds 18%.
Restricted stock award 688,000 shares Granted November 12, 2026, for annual awards for fiscal years 2027 and 2028.
Return on equity condition Exceeds 18% Fiscal 2026 condition for the 629,000-share award.
First vesting portion 50% Vests when the audited fiscal 2026 financial statements are published, if the return-on-equity condition is met.
Second vesting portion 50% Vests six months after publication of the audited fiscal 2026 financial statements, subject to continued service and the return-on-equity condition.
Fiscal 2027 award installments 344,000 shares Vests in 12 substantially equal quarterly installments beginning January 1, 2027, subject to continued service.
Fiscal 2028 award installments 344,000 shares Vests in 12 substantially equal quarterly installments beginning January 1, 2028, subject to continued service.
restricted stock award technical
"granted ... a restricted stock award"
A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.
return on equity financial
"issuer's return on equity for fiscal year 2026"
Return on equity shows how effectively a company uses its shareholders' money to generate profit. It is calculated by dividing the company's net profit by its shareholders' equity, indicating how much profit is earned for each dollar invested by owners. Higher return on equity suggests the company is good at turning investments into earnings, which can be an important factor for investors assessing its profitability and efficiency.
Amended and Restated 2019 Stock Incentive Plan technical
"under the issuer's Amended and Restated 2019 Stock Incentive Plan"
substantially equal quarterly installments technical
"in twelve substantially equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did ORMP President and CEO Nadav Kidron receive in stock awards?

Nadav Kidron received direct restricted stock awards of 629,000 shares and 688,000 shares on November 12, 2026.

What are the vesting conditions for Nadav Kidron’s 629,000-share ORMP award?

The award vests only if Oramed’s return on equity for fiscal 2026 exceeds 18%. If the condition is met, 50% vests when the audited fiscal 2026 financial statements are published and 50% six months later, subject to continued service. If it is not met, all shares are forfeited.

How does Nadav Kidron’s 688,000-share ORMP award vest?

The award vests in two groups of 344,000 shares, each in 12 substantially equal quarterly installments beginning January 1, 2027, and January 1, 2028, respectively, subject to continued service. No annual award will be granted to Kidron for fiscal 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
KIDRON NADAV

(Last)(First)(Middle)
1185 AVENUE OF THE AMERICAS
THIRD FLOOR

(Street)
NEW YORK NEW YORK 10036

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ORAMED PHARMACEUTICALS INC. [ ORMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President and CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/12/2026A629,000A(1)4,769,505D
Common Stock11/12/2026A688,000A(2)5,457,505D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 629,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan. The shares vest only if the issuer's return on equity for fiscal year 2026 exceeds 18%, in which case 50% vest on the date the issuer's audited fiscal year 2026 financial statements are published and 50% vest six months thereafter, subject to the reporting person's continued service. If the condition is not met, all of the shares will be forfeited.
2. On November 12, 2026, the issuer granted to the reporting person a restricted stock award of 688,000 shares under the issuer's Amended and Restated 2019 Stock Incentive Plan, representing the reporting person's annual awards for fiscal years 2027 and 2028. Of these shares, 344,000 vest in twelve substantially equal quarterly installments beginning January 1, 2027, and 344,000 vest in twelve substantially equal quarterly installments beginning January 1, 2028, in each case subject to the reporting person's continued service. No annual award will be granted to the reporting person for fiscal year 2028.
/s/ Nadav Kidron11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading